Abstract:Thiazolidinediones (TZDs) are peroxisomal proliferator-activated receptor (PPAR)-γ agonists. They increase insulin action through several mechanisms including: stimulation of the expression of genes that increase fat oxidation and lower plasma free fatty acid levels; increased expression, synthesis and release of adiponectin; and stimulation of adipocyte differentiation resulting in more and smaller fat cells. TZDs lower blood sugar comparably to sulfonylureas and metformin. The clinical use of TZDs is limited due to the long duration of time required before they reach their full blood sugar-lowering action (3 – 4 months) and adverse effects such as fluid retention, resulting in excessive weight gain and occasionally in peripheral and/or pulmonary oedema and congestive heart failure. Troglitazone, a TZD that has since been removed from the market because of hepatoxicity, has been demonstrated to decrease the progression from normal or impaired glucose tolerance to overt Type 2 diabetes mellitus. Pioglitazone, another TZD, marginally decreased the incidence of cardiovascular complications in patients with Type 2 diabetes mellitus (PROactive trial). Other, as yet, unapproved uses of TZDs include: non-alcoholic fatty liver disease, in which TZDs reduced hepatic fat accumulation and improved liver function tests; polycystic ovary syndrome, where TZDs improved ovulation, hirsutism and endothelial dysfunction; and lipodystrophies, where TZDs increased body fat (marginally) and decrease liver size. Lastly, because PPAR-α and -γ agonists improve atherosclerotic vascular disease and insulin sensitivity, respectively, dual PPAR-α/γ agonists, which are currently undergoing clinical trials, may be useful in treating patients with the metabolic syndrome.

Action of PPAR-γ Agonist in Lowing Blood Pressure

Recent Findings Concerning Thiazolidinediones in the Treatment of Diabetes

Effects of PPARγ Agonists Against Vascular and Renal Dysfunction

Progress in agonists and antagonists of peroxisome proliferator-activated receptor γ

Effects of thiazolidinediones on protection of the kidney

Distinct Functions of Vascular Endothelial and Smooth Muscle PPARγ in Regulation of Blood Pressure and Vascular Tone

Pharmacological Activation of PPAR Gamma Ameliorates Vascular Endothelial Insulin Resistance Via a Non-Canonical PPAR Gamma-Dependent Nuclear Factor-Kappa B Trans-Repression Pathway.

PPAR Agonists Ameliorate Endothelial Cell Activation via Inhibition of Diacylglycerol–Protein Kinase C Signaling Pathway

Pleiotropic Actions of PPAR Gamma Activators Thiazolidinediones in Cardiovascular Diseases.

Role of PPARgamma in Renoprotection in Type 2 Diabetes: Molecular Mechanisms and Therapeutic Potential.

Studies on Selective PPARγ Modulators Antidiabetic Agents in the Treatment of Type 2 Diabetes

Ppar Gamma Agonists Ameliorate Endothelial Cell Activation Via Inhibition of Diacylglycerol-Protein Kinase C Signaling Pathway - Role of Diacylglycerol Kinase

Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes

Protection of Pioglitazone for Diabetes Mellitus Beyond Its Hypoglycemic Effect

Effects of PPARγ on Hypertension, Atherosclerosis, and Chronic Kidney Disease.

The Clinical Value of Thiazolidinediones in Type 1 Diabetes

Design, synthesis and bioactivity evaluation of thiazolidinedione derivatives as partial agonists targeting PPARγ

The Actions of PPAR-γ in the Development of Hypertension and Left Ventricular Remodelling

Thiazolidinediones play a positive role in the vascular endothelium and inhibit plaque progression in diabetic patients with coronary atherosclerosis: A systematic review and meta-analysis

PPAR-γ in the Cardiovascular System

PPAR-gamma in the Cardiovascular System.